Giraldo Villa Adriana, Henao Roldan Catherine, García Loboguerrero Fanny, Martínez Volkmar María Isabel, Contreras Ramírez Mónica María, Ruiz Navas Patricia
Nutricionista clínica. Magíster en epidemiología. Grupo de Soporte Nutricional Pediátrico. Hospital Pablo Tobón Uribe. Colombia.
Nutricionista clínica. Magíster en nutrición infantil. Grupo de Soporte Nutricional Pediátrico. Hospital Pablo Tobón Uribe. Colombia.
Nutr Hosp. 2014 Apr 1;29(4):844-51. doi: 10.3305/nh.2014.29.4.7209.
Prolonged Total Parental Nutrition (TPN) is associated with life-threatening complications in the pediatric population, being cholestasis one of the most important ones. The source of fatty acids, the amount of phytosterols and the dose of lipids in the nutritional support, have been linked to the development of this complication.
To describe the behavior of liver function tests in pediatric patients with TPN where lipid based omega 3 fatty acids (OmegavenR) were used.
A retrospective research was made in a population of children under 18 years old where omega 3 fatty acids were used for a minimum of 8 days. Patients were initially classified into two groups: cholestasis and abnormal liver tests. Levels of alanine aminotransferase (ALT), aspartate aminotransferase (AST), total bilirubin (TB), direct bilirubin (DB) gamma glutamyl transferase (GGT) and alkaline phosphatase (AP) before and after treatment with OmegavenR was evaluated.
33 patients met the inclusion criteria. At the end of treatment with OmegavenR, 82.4% of patients who initially presented cholestasis showed resolution or improvement. The group of patients with abnormal liver tests 18.8% progressed to cholestasis.
Our study suggests that the use of OmegavenR in pediatric patients with TPN and DB ≥ 2 mg/dL, seem to reverse or improve cholestasis while in patients with abnormal liver tests we still don't have clear effect.
长期全胃肠外营养(TPN)在儿科人群中会引发危及生命的并发症,胆汁淤积是其中最重要的并发症之一。营养支持中脂肪酸的来源、植物甾醇的量以及脂质剂量与该并发症的发生有关。
描述在使用基于ω-3脂肪酸(OmegavenR)的TPN的儿科患者中肝功能检查的表现。
对18岁以下使用ω-3脂肪酸至少8天的儿童人群进行回顾性研究。患者最初分为两组:胆汁淤积组和肝功能检查异常组。评估使用OmegavenR治疗前后丙氨酸转氨酶(ALT)、天冬氨酸转氨酶(AST)、总胆红素(TB)、直接胆红素(DB)、γ-谷氨酰转移酶(GGT)和碱性磷酸酶(AP)的水平。
33例患者符合纳入标准。在使用OmegavenR治疗结束时,最初出现胆汁淤积的患者中有82.4%显示胆汁淤积消退或改善。肝功能检查异常的患者组中有18.8%进展为胆汁淤积。
我们的研究表明,在TPN且DB≥2mg/dL的儿科患者中使用OmegavenR似乎可逆转或改善胆汁淤积,而对于肝功能检查异常的患者,我们仍未明确其效果。